Trial Profile
Sorafenib in TACE-refractory or TACE-failure advanced hepatocellular carcinoma : Safety and effectiveness
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 May 2016
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 03 Aug 2011 New trial record
- 01 Aug 2011 Status changed from not yet recruiting to recruiting as reportrd by University Hospital Medical Information Network - Japan.